MedTrace Logo

A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)

NCT05859217 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-05-08

No results posted yet for this study

Summary

NSCLC patients with low expression level of PD-L1, esp. those with its level less than 1%, do not derive much benefit from anti-PD-1/L1 therapy (e.g. atezoilzumab). In this study, investigators hypothesize that the combination of cabozantinib (a multi-kinase inhibitor) and atezolizumab will result in better therapeutic value.

Conditions

  • Lung Cancer
  • NSCLC Stage IV
  • Metastatic NSCLC - Non-Small Cell Lung Cancer
  • Advanced NSCLC

Interventions

DRUG

Cabozantinib

Oral once per day, Days 1 - 21 every 21 days

DRUG

Atezolizumab

Intravenous (IV) once every 21 days

Sponsors & Collaborators

  • Exelixis

    collaborator INDUSTRY

  • Genentech, Inc.

    collaborator INDUSTRY

  • Jun Zhang, MD, PhD

    lead OTHER

Principal Investigators

  • Jun Zhang, MD, PhD · University of Kansas Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-31
Primary Completion
2026-06-30
Completion
2028-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05859217 on ClinicalTrials.gov